NEW YORK, May 24 (Reuters) - Neurocrine Biosciences Inc shares soared after the closing bell on Monday after it said an endometriosis drug met its goals in a study. For details see.
Shares last traded up 46.2 percent at $3.99. Keywords: MARKETS STOCKS AFTERTHEBELL (rodrigo.campos@thomsonreuters.com; + 1 646-223-6344; Reuters Messaging: rodrigo.campos.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Shares last traded up 46.2 percent at $3.99. Keywords: MARKETS STOCKS AFTERTHEBELL (rodrigo.campos@thomsonreuters.com; + 1 646-223-6344; Reuters Messaging: rodrigo.campos.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.